Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Prediction of ventricular arrhythmias in patients with a spontaneous Brugada type 1 pattern: the key is in the electrocardiogram.

Delinière A, Baranchuk A, Giai J, Bessiere F, Maucort-Boulch D, Defaye P, Marijon E, Le Vavasseur O, Dobreanu D, Scridon A, Da Costa A, Delacrétaz E, Kouakam C, Eschalier R, Extramiana F, Leenhardt A, Burri H, Winum PF, Taieb J, Bouet J, Fauvernier M, Rosianu H, Carabelli A, Duband B, Chevalier P.

Europace. 2019 Jun 9. pii: euz156. doi: 10.1093/europace/euz156. [Epub ahead of print]

PMID:
31177270
2.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 May 23;115:97-106. doi: 10.1016/j.ejca.2019.04.020. [Epub ahead of print]

PMID:
31129386
3.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparico T, Hoeffel C; PRODIGE 9 Investigators and PRODIGE 20 Investigators.

Gut. 2019 May 17. pii: gutjnl-2018-316407. doi: 10.1136/gutjnl-2018-316407. [Epub ahead of print]

PMID:
31101691
4.

Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.

Kourie H, Auclin E, Cunha AS, Gaujoux S, Bruzzi M, Sauvanet A, Lourenco N, Trouilloud I, Louafi S, El-Hajjar A, Vaillant JC, Smith D, Touchefeu Y, Bachet JB, Pietrasz D, Taieb J.

Clin Res Hepatol Gastroenterol. 2019 Apr 24. pii: S2210-7401(19)30084-1. doi: 10.1016/j.clinre.2019.03.007. [Epub ahead of print]

PMID:
31029644
5.

How is Contact Force implemented in routine clinical practice? Results from a French National and Monaco Survey.

Bun SS, Lațcu DG, Taghji P, Anselme F, Boveda S, Cebron JP, Defaye P, Deharo JC, Fauchier L, Gandjbakhch E, Gras D, Klug D, Mansourati J, Marijon E, Maury JP, Squara F, Saoudi N, Taïeb J.

J Arrhythm. 2019 Feb 15;35(2):238-243. doi: 10.1002/joa3.12165. eCollection 2019 Apr.

6.

Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data.

Boulet S, Ursino M, Thall P, Landi B, Lepère C, Pernot S, Burgun A, Taieb J, Zaanan A, Zohar S, Jannot AS.

Stat Methods Med Res. 2019 Apr 9:962280219841082. doi: 10.1177/0962280219841082. [Epub ahead of print]

PMID:
30963815
7.

Reply to the letter about the position paper concerning the competence, performance and environment required in the practice of complex ablation procedures.

Maury P, Defaye P, Klug D, Alonso C, Anselme F, Fauchier L, Gandjbakhch E, Gras D, Hermida JS, Laurent G, Mansourati J, Marijon E, Sacher F, Taieb J, Boveda S, Piot O, Sadoul N; Working Group on Pacing, Electrophysiology of the French Society of Cardiology.

Arch Cardiovasc Dis. 2019 Apr;112(4):290-291. doi: 10.1016/j.acvd.2018.11.012. Epub 2019 Mar 18. No abstract available.

PMID:
30898475
8.

How to better select patients with advanced gastric cancer for immunotherapy.

Zaanan A, Taieb J.

Transl Gastroenterol Hepatol. 2019 Jan 31;4:6. doi: 10.21037/tgh.2019.01.06. eCollection 2019. No abstract available.

9.

How best to treat older patients with metastatic colorectal cancer?

Taieb J.

Lancet Gastroenterol Hepatol. 2019 May;4(5):331-333. doi: 10.1016/S2468-1253(19)30076-7. Epub 2019 Mar 7. No abstract available.

PMID:
30852135
10.

Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.

Taieb J, André T, Auclin E.

Cancer Treat Rev. 2019 May;75:1-11. doi: 10.1016/j.ctrv.2019.02.002. Epub 2019 Feb 26. Review.

PMID:
30849607
11.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.

Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, Merabtene F, Dumont S, Sauvanet A, Hammel P, Cros J, André T, Bachet JB, Bardier A, Douard R, Meatchi T, Peschaud F, Emile JF, Cojean-Zelek I, Laurent-Puig P, Taieb J.

Br J Cancer. 2019 Apr;120(7):697-702. doi: 10.1038/s41416-019-0415-8. Epub 2019 Mar 6.

PMID:
30837681
12.

Relationship between vitamin D status in pregnancy and the risk for preeclampsia: A nested case-control study.

Benachi A, Baptiste A, Taieb J, Tsatsaris V, Guibourdenche J, Senat MV, Haidar H, Jani J, Guizani M, Jouannic JM, Haguet MC, Winer N, Masson D, Courbebaisse M, Elie C, Souberbielle JC.

Clin Nutr. 2019 Feb 15. pii: S0261-5614(19)30069-X. doi: 10.1016/j.clnu.2019.02.015. [Epub ahead of print]

PMID:
30799191
13.

Occurrence of significant long PR intervals in patients implanted for sinus node dysfunction and monitored with SafeR™: The PRECISE study.

Taieb J, Le Franc P, Khattar P, Moubarak G, Gorka H, Godenir JP, Deutsch P, Degand B, Al Daoud A, Elkaim JP, Elbaz N, Merlo S, Lellouche N.

Arch Cardiovasc Dis. 2019 Mar;112(3):153-161. doi: 10.1016/j.acvd.2018.09.005. Epub 2018 Dec 26.

14.

[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

Zaanan A, Taieb J.

Bull Cancer. 2019 Feb;106(2):129-136. doi: 10.1016/j.bulcan.2018.10.011. Epub 2018 Dec 4. Review. French.

PMID:
30527814
15.

Inter-mesenteric connections between the superior and inferior mesenteric arteries for left colonic vascularization: implications for colorectal surgery.

Bruzzi M, M'harzi L, El Batti S, Ghazaleh RA, Taieb J, Poghosyan T, Berger A, Chevallier JM, Douard R.

Surg Radiol Anat. 2019 Mar;41(3):255-264. doi: 10.1007/s00276-018-2139-5. Epub 2018 Nov 26.

PMID:
30478643
16.

Author Correction: Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.

Bibault JE, Giraud P, Housset M, Durdux C, Taieb J, Berger A, Coriat R, Chaussade S, Dousset B, Nordlinger B, Burgun A.

Sci Rep. 2018 Nov 12;8(1):16914. doi: 10.1038/s41598-018-35359-7.

17.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J.

Clin Colorectal Cancer. 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19.

PMID:
30415988
18.

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

Moehler M, Ryu MH, Dvorkin M, Lee KW, Coşkun HŞ, Wong R, Chung HC, Poltoratsky A, Tsuji A, Yen CJ, Muntean AS, Le Sourd S, Vaccaro GM, Overton L, Boku N, Wainberg ZA, Patel M, Sharma M, Xiong H, Conti I, Taieb J, Bang YJ.

Future Oncol. 2019 Feb;15(6):567-577. doi: 10.2217/fon-2018-0668. Epub 2018 Oct 31.

19.

How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.

Pietrasz D, Turrini O, Vendrely V, Simon JM, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N, Goere D, Artru P, Vaillant JC, Huguet F, Laurent C, Sauvanet A, Delpero JR, Bachet JB, Sa Cunha A.

Ann Surg Oncol. 2019 Jan;26(1):109-117. doi: 10.1245/s10434-018-6931-6. Epub 2018 Oct 25.

PMID:
30362063
20.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

Bachet JB, Lucidarme O, Levache CB, Barbier E, Raoul JL, Lecomte T, Desauw C, Brocard F, Pernot S, Breysacher G, Lagasse JP, Di Fiore F, Etienne PL, Dupuis OJM, Aleba A, Lepage C, Taieb J; for FFCD 1102 investigators.

Eur J Cancer. 2018 Nov;104:108-116. doi: 10.1016/j.ejca.2018.09.006. Epub 2018 Oct 18.

PMID:
30343254
21.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.

Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J.

Ann Oncol. 2019 Jan 1;30(1):124-131. doi: 10.1093/annonc/mdy461.

22.

Noninvasive detection of atrial fibrillation in cryptogenic stroke: Contribution of a new e-cardiology device.

Tarlet JM, Taieb J, Di Legge S, Boccara G, Coulon D, Guenoun M.

HeartRhythm Case Rep. 2018 Jun 22;4(9):412-414. doi: 10.1016/j.hrcr.2018.06.006. eCollection 2018 Sep. No abstract available.

23.

Vitamin D status during pregnancy and in cord blood in a large prospective French cohort.

Courbebaisse M, Souberbielle JC, Baptiste A, Taieb J, Tsatsaris V, Guibourdenche J, Senat MV, Haidar H, Jani J, Guizani M, Jouannic JM, Haguet MC, Winer N, Masson D, Elie C, Benachi A.

Clin Nutr. 2018 Aug 31. pii: S0261-5614(18)32429-4. doi: 10.1016/j.clnu.2018.08.035. [Epub ahead of print]

PMID:
30224306
24.

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD); Société Nationale Française de Gastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Française de Chirurgie Digestive (SFCD); Société Française d’Endoscopie Digestive (SFED); Société Française de Radiothérapie Oncologique (SFRO); Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT); Association Française de Chirurgie (AFC).

Dig Liver Dis. 2018 Dec;50(12):1257-1271. doi: 10.1016/j.dld.2018.08.008. Epub 2018 Aug 18. Review.

PMID:
30219670
25.

Position paper concerning the competence, performance and environment required in the practice of complex ablation procedures.

Maury P, Defaye P, Klug D, Alonso C, Anselme F, Fauchier L, Gandjbakhch E, Gras D, Hermida JS, Laurent G, Mansourati J, Marijon E, Sacher F, Taieb J, Boveda S, Piot O, Sadoul N; Working Group of Pacing, Electrophysiology of the French Society of Cardiology.

Arch Cardiovasc Dis. 2019 Jan;112(1):67-73. doi: 10.1016/j.acvd.2018.05.006. Epub 2018 Aug 27.

PMID:
30166064
26.

Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.

Bibault JE, Giraud P, Housset M, Durdux C, Taieb J, Berger A, Coriat R, Chaussade S, Dousset B, Nordlinger B, Burgun A.

Sci Rep. 2018 Aug 22;8(1):12611. doi: 10.1038/s41598-018-30657-6. Erratum in: Sci Rep. 2018 Nov 12;8(1):16914.

27.

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J.

Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.

28.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C.

Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.

PMID:
30042063
29.

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.

Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A, Gebski V, Van Buskirk M, Zhao H, van Hazel G; SIRFLOX and FOXFIRE Global Trial Investigators.

Clin Colorectal Cancer. 2018 Dec;17(4):e617-e629. doi: 10.1016/j.clcc.2018.06.001. Epub 2018 Jun 12.

PMID:
30033117
30.

Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men.

Pernot S, Boucheron P, Péré H, Lucas ML, Veyer D, Fathallah N, de Parades V, Pavie J, Netter J, Collias L, Taieb J, Grabar S, Weiss L.

Br J Cancer. 2018 Aug;119(3):381-386. doi: 10.1038/s41416-018-0176-9. Epub 2018 Jul 20.

PMID:
30026613
31.

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.

Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S.

Br J Cancer. 2018 Aug;119(3):303-312. doi: 10.1038/s41416-018-0165-z. Epub 2018 Jul 17.

32.

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer-Reply.

Taieb J.

JAMA Oncol. 2018 Sep 1;4(9):1298. doi: 10.1001/jamaoncol.2018.1718. No abstract available.

PMID:
30003228
33.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

PMID:
29921730
34.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study.

Pernot S, Dubreuil O, Aparicio T, Le Malicot K, Tougeron D, Lepère C, Lecaille C, Marthey L, Palle J, Bachet JB, Zaanan A, Taieb J.

Br J Cancer. 2018 Aug;119(4):424-428. doi: 10.1038/s41416-018-0133-7. Epub 2018 Jun 6.

PMID:
29872148
35.

Reply to M. Mo et al.

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bennouna J.

J Clin Oncol. 2018 Aug 10;36(23):2452-2453. doi: 10.1200/JCO.2018.78.9669. Epub 2018 Jun 4. No abstract available.

PMID:
29863977
36.

Colorectal Cancer: Why Does Side Matter?

Gallois C, Pernot S, Zaanan A, Taieb J.

Drugs. 2018 Jun;78(8):789-798. doi: 10.1007/s40265-018-0921-7. Review.

PMID:
29790124
37.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

Aparicio T, Bouché O, Francois E, Retornaz F, Barbier E, Taieb J, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Bedenne L, Paillaud E; for PRODIGE 20 investigators.

Eur J Cancer. 2018 Jul;97:16-24. doi: 10.1016/j.ejca.2018.03.030. Epub 2018 May 16.

PMID:
29777975
38.

[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]

André T, Taieb J; Pour l’intergroupe PRODIGE (GERCOR, Fédération française de cancérologie digestive, et Unicancer) et pour la Fondation ARCAD (Aide et recherche encancérologie digestive).

Bull Cancer. 2018 Jun;105(6):546-547. doi: 10.1016/j.bulcan.2018.04.002. French. No abstract available.

PMID:
29776587
39.

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.

Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D.

ESMO Open. 2018 May 5;3(4):e000353. doi: 10.1136/esmoopen-2018-000353. eCollection 2018. Review.

40.

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

Auclin E, André T, Taieb J, Benetkiewicz M, de Gramont A, Vernerey D.

Eur J Cancer. 2018 Jul;97:55-56. doi: 10.1016/j.ejca.2018.03.032. Epub 2018 May 3. No abstract available.

PMID:
29731226
41.

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ.

Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22. Review.

42.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; for PRODIGE 20 Investigators.

Ann Oncol. 2018 Nov 1;29(11):2270. doi: 10.1093/annonc/mdx808. No abstract available.

43.

Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.

Peeters M, Cervantes A, Moreno Vera S, Taieb J.

Future Oncol. 2018 Jul;14(16):1629-1645. doi: 10.2217/fon-2018-0147. Epub 2018 Apr 27. Review.

44.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

Moati E, Taly V, Didelot A, Perkins G, Blons H, Taieb J, Laurent-Puig P, Zaanan A.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):396-402. doi: 10.1016/j.clinre.2018.03.002. Epub 2018 Apr 5.

PMID:
29627453
45.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.

J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.

PMID:
29620995
46.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T.

N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.

47.

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.

Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J.

Ann Oncol. 2018 Apr 1;29(4):835-856. doi: 10.1093/annonc/mdy038.

48.

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.

Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M.

J Cancer Res Clin Oncol. 2018 Apr;144(4):795-797. doi: 10.1007/s00432-018-2591-y.

PMID:
29450632
49.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.

Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.

PMID:
29438522
50.

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, André T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A.

Ann Oncol. 2018 May 1;29(5):1099-1107. doi: 10.1093/annonc/mdy064.

PMID:
29438451

Supplemental Content

Support Center